Clinical Psychopharmacology Institute Faculty

Wilson Compton, MD, MPE

Deputy Director
National Institute on Drug Abuse (NIDA) of the National Institutes of Health

Keynote Speaker

Anyi Atabong, DNP, PMHNP-BC, FNP-C, PMH-C

CEO & Co-Founder, Capital Multi Health Group; Adjunct Faculty, Georgetown University Berkley School of Nursing and Co-Founder of The Society of PMHNPs of Color

Timing, Treatment, Trust: Shaping the Trajectory of Bipolar Disorder

Lee Cohen, MD

Director, The Ammon-Pinizzotto Center for Women’s Mental Health; Associate Chief of Psychiatry for Philanthropy and Department Communications, Massachusetts General Hospital

Women’s mental health

Oliver Freudenreich, MD, FACLP

Professor of Clinical Psychiatry, Harvard Medical School; Co-Director, MGH Psychosis Clinical and Research Program
Massachusetts General Hospital

Treatment as Prevention: Stage-Based Schizophrenia Care

Lyons Hardy, MSN, PMHNP

Associate Professor, Virginia Commonwealth University

Dementia types and psychopharmacology

Laura Leahy DrNP, APRN, FAANP, FAANB

Board Certified Psychiatric & Addictions Advanced Practice Nurse; Founder, APNSolutions, LLC

Revisiting older medications

Jeremy Mills, DNP, APRN, PMHNP-BC

Clinical Assistant Professor, Coordinator, Psychiatric-Mental Health Nurse Practitioner Program, University of Tennessee

Treatment for nicotine cessation, including vaping

Anthony L. Rostain, MD, MA

Chair, Department of Psychiatry & Behavioral Health, Cooper University Health Care; Professor of Psychiatry & Pediatrics, Cooper Medical School of Rowan University

ADHD & neurodevelopmental disorders across the lifespan

Natalie Taylor, PMHNP-BC

Medical Director, Wild Oaks & Richmond Creative Counseling

Eating Disorders

Tony Thrasher, DO, MBA, CPE, DFAPA

Medical Director of Crisis Services, Milwaukee County Behavioral Health Division

Emergency room psychiatry

Glenn J. Treisman, MD, PhD

Eugene Meyer III Professor of Psychiatry & Medicine, Director of AIDS Psychiatry Services, Director of the Pain Treatment Program, Johns Hopkins University School of Medicine, Co-Director of the Amos Food, Body & Mind Center

Psychopharmacology in underserved populations

Jared Vega, JD, FNP, Psych NP

Psychiatric-Mental Health Nurse Practitioner

Prescribing with Protection: Legal Implications and Documentation for PMHNPs in Psychopharmacology

Kirby Williams, MSN, PMHNP-BC

Founder, The PMHNP Source & Beacon Behavioral Health and Consulting; Co-founder, The Society of PMHNPs of Color

Drug-Induced Movement Disorders: From Recognition to Real-World Management

Wilson Compton, MD, MPE

Deputy Director
National Institute on Drug Abuse (NIDA) of the National Institutes of Health

Keynote Speaker

Anyi Atabong, DNP, PMHNP-BC, FNP-C, PMH-C

CEO & Co-Founder, Capital Multi Health Group; Adjunct Faculty, Georgetown University Berkley School of Nursing and Co-Founder of The Society of PMHNPs of Color

Timing, Treatment, Trust: Shaping the Trajectory of Bipolar Disorder

Lee Cohen, MD

Director, The Ammon-Pinizzotto Center for Women’s Mental Health; Associate Chief of Psychiatry for Philanthropy and Department Communications, Massachusetts General Hospital

Women’s mental health

Oliver Freudenreich, MD, FACLP

Professor of Clinical Psychiatry, Harvard Medical School; Co-Director, MGH Psychosis Clinical and Research Program
Massachusetts General Hospital

Treatment as Prevention: Stage-Based Schizophrenia Care

Regular Conference Program

5:30pm-7:30pm Eastern | 2 Pharmacology Contact Hours

Prescribing with Protection: Legal Implications and Documentation for PMHAPRNs in Psychopharmacology 

Jared Vega, JD, FNP, Psych NP

Have you ever wondered what really happens when a prescribing decision gets looked at by an attorney or your state board? Explore real-life malpractice and State Board actions, review legal pitfalls in psychopharmacology and prescribing, plus documentation best practices to help you protect your license.

Product Theater Dinner

8:00pm-9:30pm Eastern | No Contact Hours Provided